☏ +1 650 501 5505 ✉ [email protected]
Drug Pipeline Review Therapy area: Systemic Sclerosis40–50 pages · PDF + Excel tracker

Systemic Sclerosis Drug Pipeline: 69 Assets by Phase

Systemic Sclerosis pipeline: 69 drug candidates in clinical development, 10 in Phase III, from 52 sponsors. Data as of 3 Oct 2026.

Pipeline Terminal Systemic Sclerosis Data as of 3 Oct 2026
Candidates in development 69assets Desk-reviewed How this number is madeEvery drug named in an interventional trial, merged across code, generic and brand names, with a live or recent industry trial. Placebo and comparator arms excluded.
Phase III 1014% of pipeline Registry How this number is madeCandidates whose highest phase in a live or recent trial is Phase III (Phase II/III counts as Phase II).
Phase II 1826% of pipeline Registry
Phase I 4159% of pipeline Registry
Sponsors 52top 5 hold 22% Registry How this number is madeCompanies credited with at least one candidate: the lead sponsor on most of that candidate's industry trials.
Registered trials 263157 running Registry How this number is madeInterventional trials on ClinicalTrials.gov for the conditions in scope, updated since 3 Oct 2021.
Readouts in 12 months 8Phase II or later Sponsor dates How this number is madeCandidates with a registered primary completion date in the next 12 months. Dates are the sponsor's own and often move.
Trials with US sites 8633% · Europe 31% Registry How this number is madeTrials with at least one site in the United States; Europe is the EU/EEA, the UK and Switzerland. A trial counts in every region where it has a site.

Candidates by highest phase reached

Phase I41
Phase II18
Phase III10

Next registered primary completions, Phase II or later

CandidatePhasePrimary completion
TOP-N53Phase IIOct 2026 (est.)
SildenafilPhase IIOct 2026 (est.)
AnifrolumabPhase IIIJan 2027 (est.)

Candidates in development by lead sponsor

Boehringer Ingelheim3
Fate Therapeutics3
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company3
Nanjing Bioheng Biotech Co., Ltd.3
Century Therapeutics, Inc.3

Phase II and III primary completions per quarter

Q4 20262
Q1 20273
Q2 20272
Q3 20271
Q4 20274
Q1 20281
Q2 20281
Q3 20281

Answers at a glance

  • 10 of 69 systemic sclerosis candidates (14%) are in Phase III.
  • Boehringer Ingelheim runs the largest systemic sclerosis pipeline, with 3 candidates.
  • 8 readouts are due in 12 months; the next is TOP-N53 in Oct 2026.
  • 94 trials are recruiting patients now; 33% of all trials have a US site and 31% a European one.
69 candidates263 trials59 countriesData as of 3 Oct 2026Next refresh by 1 Jan 2027
USD 3,000Pipeline Snapshot Download Free Sample Request the Review
Edition: data as of 3 Oct 2026 Next refresh: by 1 Jan 2027 Change: First edition

Request a free sample

A sample of the Systemic Sclerosis Pipeline Review: the full chapter list, the tracker columns and two asset profiles from the report. The Research Desk reviews your request and emails it, usually within one business day.

Systemic Sclerosis has 69 drug candidates in active clinical development, of which 10 are in Phase III, 18 in Phase II and 41 in Phase I, according to Douglas Insights' count of 263 interventional trials registered on ClinicalTrials.gov (data as of 3 Oct 2026).

The systemic sclerosis drug pipeline is the set of medicines that sponsors are still testing in people for this condition: each candidate is counted once, at the highest phase it has reached in a running or recently completed trial. Medicines already on the market and studied only in Phase IV trials are kept out of the count.

How many systemic sclerosis drugs are in each phase of development?

Douglas Insights counts 10 systemic sclerosis candidates in Phase III, 14% of the 69 assets in development; Phase II holds 18 and Phase I holds 41.

Phase I41Phase II18Phase III10
Candidates by highest phase reached. Source: Douglas Insights from ClinicalTrials.gov, data as of 3 Oct 2026.
Phase (highest reached)AssetsShare of pipeline
Phase III1014%
Phase II1826%
Phase I4159%
Total69100%

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each systemic sclerosis asset appears in exactly one row. The 157 trials still recruiting or running carry 60% of the 263 registered trials in scope.

How many systemic sclerosis trials are recruiting patients now?

94 systemic sclerosis trials are recruiting patients and 39 more have not started recruiting yet, out of 263 interventional trials in scope; together they make up 51% of the trial base.

Registry statusTrialsShare
Recruiting9436%
Completed5922%
Not yet recruiting3915%
Terminated207.6%
Active, not recruiting197.2%
Status not verified166.1%
Withdrawn62.3%
Enrolling by invitation51.9%
Suspended51.9%

Terminated, suspended and withdrawn systemic sclerosis trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the systemic sclerosis pipeline?

Boehringer Ingelheim leads the systemic sclerosis pipeline with 3 candidates; the top 5 sponsors hold 22% of the 69 assets, and 52 sponsors run at least one.

SponsorAssets in developmentShare
Boehringer Ingelheim34.3%
Fate Therapeutics34.3%
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company34.3%
Nanjing Bioheng Biotech Co., Ltd.34.3%
Century Therapeutics, Inc.34.3%

Industry sponsors lead 120 of the 263 systemic sclerosis trials (46%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the systemic sclerosis pipeline?

Mechanism and drug-type classification for the 69 systemic sclerosis candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What systemic sclerosis trial readouts are coming next?

8 systemic sclerosis candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

CandidateSponsorPhasePrimary completionRegistry
TOP-N53Topadur Pharma AGPhase IIOct 2026 (estimated)NCT06954597
SildenafilTopadur Pharma AGPhase IIOct 2026 (estimated)NCT06954597
AnifrolumabAstraZenecaPhase IIIJan 2027 (estimated)NCT05925803

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many systemic sclerosis readouts fall in each quarter?

15 systemic sclerosis candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 4, due in Q4 2027.

QuarterPhase III readoutsPhase II readoutsTotal
Q4 2026022
Q1 2027123
Q2 2027022
Q3 2027011
Q4 2027314
Q1 2028011
Q2 2028011
Q3 2028101

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most systemic sclerosis trials?

United States hosts the most systemic sclerosis trials, with sites in 86 of the 263 studies (33%); trials in scope run in 59 countries in all.

CountryTrials with a siteShare of trials
United States8633%
China8231%
France4818%
United Kingdom3513%
Spain3112%
Germany3011%
Canada2710%
Italy269.9%

A multinational systemic sclerosis trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are systemic sclerosis drugs being tested?

86 of the 263 systemic sclerosis trials (33%) have a site in the United States, 82 (31%) in Europe and 82 (31%) in China; 42 of the 69 candidates in development are tested in the US.

RegionTrials with a siteShare of trialsCandidates testedRegulator
United States8633%42FDA
Europe (EU/EEA, UK, Switzerland)8231%29EMA, MHRA, Swissmedic
China8231%25NMPA
Japan176.5%13PMDA
Rest of world7027%29national regulators

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational systemic sclerosis trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the systemic sclerosis pipeline since the last update?

This is the first edition of the systemic sclerosis pipeline count, dated 3 Oct 2026. The next refresh is due by 1 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the systemic sclerosis pipeline?

Douglas Insights read 263 interventional trials registered on ClinicalTrials.gov for the conditions "Scleroderma, Systemic", "Systemic Sclerosis" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 69 unique candidates.

  1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
  2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
  3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
  4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

What does the Systemic Sclerosis Pipeline Review include?

The Systemic Sclerosis Pipeline Review covers all 69 candidates in an Excel tracker and profiles the leading 25 in a 40–50 page report, ending with the research desk's ranked view of the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of all 69 candidates
01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where systemic sclerosis treatment is heading.

  • Pipeline size and phase mix
  • The three calls that matter
  • What changed since the last edition
02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

  • Patient population and diagnosis
  • Treatment guidelines and gaps
  • Regulatory endpoints
03Approved therapies3 pp

The marketed medicines every systemic sclerosis candidate will be measured against.

  • Marketed medicines and their sponsors
  • Post-approval trials
  • The bar a new entrant must clear
04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

  • Assets by phase and drug type
  • Sponsors by size of pipeline
  • Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

  • Mechanism classes and crowding
  • Classes with no candidate yet
  • Differentiation by route and dosing
06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

  • Design and endpoints of the pivotal trials
  • Data to date, with sources
  • Next readout and the risk to it
07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

  • Readouts by quarter
  • Filings and regulatory decisions
  • Date confidence for each event
08Deals and partnering3 pp

Who is licensing, buying and partnering in systemic sclerosis, and on what terms.

  • Licensing and M&A in the area
  • Deal terms where disclosed
  • Sponsors open to partnering
09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

  • Pipeline share by sponsor
  • Sponsor-by-phase matrix
  • New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

  • Ranked candidates
  • Risks that could change the order
  • Openings for new entrants and investors
11Methodology and source log2 pp

How the count is built and every document behind it.

  • How candidates are counted and merged
  • Every source document listed
  • The ten quality checks

Ways to buy the Systemic Sclerosis review

OptionWhat you getDeliveryPrice
Pipeline SnapshotThis therapy area as published: PDF report + Excel trackerReady nowUSD 3,000Enquire
Pipeline ReviewYour indication, geography and phase cut-off; ranked calls and an analyst call2–3 weeksFrom USD 4,000Enquire
Company AssessmentOne sponsor's full pipeline against its peers2 weeksFrom USD 5,000Enquire

Email me the sample and chapter listAsk for a quote

Frequently asked questions about the systemic sclerosis pipeline

How many drugs are in the systemic sclerosis pipeline?

69 drug candidates are in active clinical development for systemic sclerosis, with 10 in Phase III, per Douglas Insights (data as of 3 Oct 2026).

Which company has the most systemic sclerosis drugs in development?

3 candidates make Boehringer Ingelheim the largest systemic sclerosis pipeline sponsor, out of 52 sponsors counted by Douglas Insights.

When is the next systemic sclerosis trial readout?

Oct 2026 is the registered primary completion of the Phase II trial of TOP-N53 (NCT06954597), the next systemic sclerosis catalyst in Douglas Insights' calendar.

How many systemic sclerosis trials run in the United States and Europe?

86 systemic sclerosis trials have a US site and 82 a European site, out of 263 registered trials counted by Douglas Insights (data as of 3 Oct 2026).

How often is the systemic sclerosis pipeline count updated?

90 days is the refresh cycle; this edition uses registry data as of 3 Oct 2026 and the next is due by 1 Jan 2027.

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this page Douglas Insights (2026). Systemic Sclerosis Drug Pipeline, data as of 3 Oct 2026. https://www.douglasinsights.com/pipeline/systemic-sclerosis/